Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) treatment has changed in the past ten years due to the acceptance of platinumbased adjuvant chemotherapy. In the event of relapse, patients are often retreated with platinum agents. Hypersensitivity reactions to carboplatin are well documented among gynecologic oncology patients. Now that adjuvant chemotherapy is a component of NSCLC treatment, platinum hypersensitivity is also a concern in the lung cancer population. A 74-yearold male developed relapsed NSCLC two years after a lobectomy and adjuvant chemotherapy including carboplatin. He was treated with a carboplatin containing regimen, and experienced hypersensitivity during his 2^nd cycle (post-relapse). We briefly report four additional cases of platinum sensitivity in NSCLC patients, to highlight the increasing likelihood of platinum hypersensitivity in this “at risk” group. Hypersensitivity reactions to platinum chemotherapeutics occur in NSCLC patients, and patients and treating medical staff should be aware of this serious, treatment-related complication.